Applied DNA provides investor presentation with no new material disclosures

BNB PLUS CORP.

Company filed a presentation for investor use; no financial results or guidance included.
Presentation emphasizes cell-free enzymatic DNA platform for genetic medicines.
No specific data on revenue, contracts, or milestones disclosed in the filing.
Risks highlighted include history of net losses and going concern doubt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.